Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

HeartSciences (HSCS) Non-Current Assets (2021 - 2025)

Historic Non-Current Assets for HeartSciences (HSCS) over the last 5 years, with Q4 2025 value amounting to $2.2 million.

  • HeartSciences' Non-Current Assets rose 548.15% to $2.2 million in Q4 2025 from the same period last year, while for Oct 2025 it was $8.3 million, marking a year-over-year decrease of 135.28%. This contributed to the annual value of $2.1 million for FY2025, which is 454.9% down from last year.
  • As of Q4 2025, HeartSciences' Non-Current Assets stood at $2.2 million, which was up 548.15% from $2.0 million recorded in Q3 2025.
  • In the past 5 years, HeartSciences' Non-Current Assets registered a high of $2.2 million during Q4 2025, and its lowest value of $130793.0 during Q3 2022.
  • For the 5-year period, HeartSciences' Non-Current Assets averaged around $1.3 million, with its median value being $1.3 million (2022).
  • As far as peak fluctuations go, HeartSciences' Non-Current Assets crashed by 4519.39% in 2022, and later skyrocketed by 33482.91% in 2023.
  • HeartSciences' Non-Current Assets (Quarter) stood at $289329.0 in 2021, then skyrocketed by 122.48% to $643706.0 in 2022, then decreased by 13.6% to $556147.0 in 2023, then soared by 275.47% to $2.1 million in 2024, then increased by 5.48% to $2.2 million in 2025.
  • Its last three reported values are $2.2 million in Q4 2025, $2.0 million for Q3 2025, and $2.1 million during Q2 2025.